Cargando…

Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life

Objective: Evaluate bioequivalence, based on norelgestromin (NGMN) and ethinyl estradiol (EE) plasma concentrations, and adhesion of a transdermal contraceptive patch containing a newly sourced adhesive component (test) at end of shelf life (EOSL) vs. the marketed EVRA patch (reference) at beginning...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanga, Madhu, Vaughan, Subusola, Nangosyah, Julius, Scholz, Veronika, Fonseca, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670371/
https://www.ncbi.nlm.nih.gov/pubmed/34779392
http://dx.doi.org/10.5414/CP204034
_version_ 1784614967179214848
author Sanga, Madhu
Vaughan, Subusola
Nangosyah, Julius
Scholz, Veronika
Fonseca, Sergio
author_facet Sanga, Madhu
Vaughan, Subusola
Nangosyah, Julius
Scholz, Veronika
Fonseca, Sergio
author_sort Sanga, Madhu
collection PubMed
description Objective: Evaluate bioequivalence, based on norelgestromin (NGMN) and ethinyl estradiol (EE) plasma concentrations, and adhesion of a transdermal contraceptive patch containing a newly sourced adhesive component (test) at end of shelf life (EOSL) vs. the marketed EVRA patch (reference) at beginning of shelf life (BOSL). Materials and methods: In this randomized, double-blind, two-way crossover study, healthy women received a single, 7-day application of test and reference patches in 4 sequences: two 11-day treatment periods separated by a 21-day washout. Assessments included NGMN and EE pharmacokinetics (PK), adhesion (per European Medicines Agency (EMA) 5-point scale), irritation potential and application-site reactions, and tolerability. Patches were bioequivalent if 90% CIs of geometric mean ratios (GMRs) of test/reference for C(max), AUC(168h), AUC(0–tlast), and AUC(∞) were 80 – 125%. Patch adhesion was comparable if ratios of geometric mean cumulative adhesion percentages were ≥ 90%. Results: 68 women were randomized, and 62 completed both treatments. 55 and 59 participants in the reference and test group, respectively, had patch adhesion ≥ 80% (EMA score 0 – 1) at end of treatment. Bioequivalence was demonstrated: GMRs for pharmacokinetic (PK) parameters ranged from 102.76 to 105.57% for NGMN and 93.78 – 94.80% for EE, and associated 90% CIs were fully within the bioequivalence acceptance range (80 – 125%) for both. The patches had comparable adhesion properties (GMR, 101.4% (90% CI: 99.2 – 103.6)) and incidences of treatment-emergent adverse events. Conclusion: NGMN-EE transdermal test patch at EOSL was bioequivalent to the marketed patch at BOSL, supporting widening the product’s shelf-life specification. Adhesive properties and safety profiles were comparable between patches.
format Online
Article
Text
id pubmed-8670371
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-86703712022-01-01 Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life Sanga, Madhu Vaughan, Subusola Nangosyah, Julius Scholz, Veronika Fonseca, Sergio Int J Clin Pharmacol Ther Research Article Objective: Evaluate bioequivalence, based on norelgestromin (NGMN) and ethinyl estradiol (EE) plasma concentrations, and adhesion of a transdermal contraceptive patch containing a newly sourced adhesive component (test) at end of shelf life (EOSL) vs. the marketed EVRA patch (reference) at beginning of shelf life (BOSL). Materials and methods: In this randomized, double-blind, two-way crossover study, healthy women received a single, 7-day application of test and reference patches in 4 sequences: two 11-day treatment periods separated by a 21-day washout. Assessments included NGMN and EE pharmacokinetics (PK), adhesion (per European Medicines Agency (EMA) 5-point scale), irritation potential and application-site reactions, and tolerability. Patches were bioequivalent if 90% CIs of geometric mean ratios (GMRs) of test/reference for C(max), AUC(168h), AUC(0–tlast), and AUC(∞) were 80 – 125%. Patch adhesion was comparable if ratios of geometric mean cumulative adhesion percentages were ≥ 90%. Results: 68 women were randomized, and 62 completed both treatments. 55 and 59 participants in the reference and test group, respectively, had patch adhesion ≥ 80% (EMA score 0 – 1) at end of treatment. Bioequivalence was demonstrated: GMRs for pharmacokinetic (PK) parameters ranged from 102.76 to 105.57% for NGMN and 93.78 – 94.80% for EE, and associated 90% CIs were fully within the bioequivalence acceptance range (80 – 125%) for both. The patches had comparable adhesion properties (GMR, 101.4% (90% CI: 99.2 – 103.6)) and incidences of treatment-emergent adverse events. Conclusion: NGMN-EE transdermal test patch at EOSL was bioequivalent to the marketed patch at BOSL, supporting widening the product’s shelf-life specification. Adhesive properties and safety profiles were comparable between patches. Dustri-Verlag Dr. Karl Feistle 2022-01 2021-11-15 /pmc/articles/PMC8670371/ /pubmed/34779392 http://dx.doi.org/10.5414/CP204034 Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sanga, Madhu
Vaughan, Subusola
Nangosyah, Julius
Scholz, Veronika
Fonseca, Sergio
Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life
title Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life
title_full Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life
title_fullStr Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life
title_full_unstemmed Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life
title_short Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life
title_sort randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the evra patch at the beginning of shelf life
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670371/
https://www.ncbi.nlm.nih.gov/pubmed/34779392
http://dx.doi.org/10.5414/CP204034
work_keys_str_mv AT sangamadhu randomizeddoubleblindtwowaycrossoverbioequivalenceandadhesionstudyinhealthywomenofatransdermalcontraceptivepatchwithanewlysourcedadhesivecomponentattheendofshelflifevstheevrapatchatthebeginningofshelflife
AT vaughansubusola randomizeddoubleblindtwowaycrossoverbioequivalenceandadhesionstudyinhealthywomenofatransdermalcontraceptivepatchwithanewlysourcedadhesivecomponentattheendofshelflifevstheevrapatchatthebeginningofshelflife
AT nangosyahjulius randomizeddoubleblindtwowaycrossoverbioequivalenceandadhesionstudyinhealthywomenofatransdermalcontraceptivepatchwithanewlysourcedadhesivecomponentattheendofshelflifevstheevrapatchatthebeginningofshelflife
AT scholzveronika randomizeddoubleblindtwowaycrossoverbioequivalenceandadhesionstudyinhealthywomenofatransdermalcontraceptivepatchwithanewlysourcedadhesivecomponentattheendofshelflifevstheevrapatchatthebeginningofshelflife
AT fonsecasergio randomizeddoubleblindtwowaycrossoverbioequivalenceandadhesionstudyinhealthywomenofatransdermalcontraceptivepatchwithanewlysourcedadhesivecomponentattheendofshelflifevstheevrapatchatthebeginningofshelflife